The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has created a significant threat to global health. Since effective treatments and vaccines are currently not available, diligent attention on transmission-based precautions is essential to limit viral spread. According to current evidence, SARS-CoV-2 is mainly transmitted through respiratory droplets exhaled from infected individuals \[[@CIT0001]\]. Importantly, viral loads are high in the nasal cavity, nasopharynx, and oropharynx and viral shedding can be detected before, during, and after the acute clinical phase of illness \[[@CIT0002]\]. Aerosols produced by asymptomatic individuals during breathing, speaking, and singing are therefore considered critical drivers of the enhanced spread of SARS-CoV-2 \[[@CIT0003]\]. The host cell-derived envelope of SARS-CoV-2 is highly susceptible to chemical agents (ie, various alcohols) that disrupt lipid biomembranes \[[@CIT0004]\]. Chemical antisepsis thus provides a critical tool to decontaminate fomites and (body) surfaces such as human hands. In this context, nasal and oral antisepsis have been suggested to lower the number of active aerosolized virus particles from the nasal passages and oral cavity and consequently reduce transmission risk of SARS-CoV-2 \[[@CIT0005]\]. Antiseptic mouth rinses with antimicrobial activity are used in various clinical situations for prophylactic and therapeutic purposes and have further been applied in the context of viral infections \[[@CIT0005]\]. Although various commercially available dental mouthwashes contain membrane-damaging agents (ie, ethanol, chlorhexidine, cetylpyridinium chloride, hydrogen peroxide, and povidone-iodine), their ability to inactivate SARS-CoV-2 under biologically relevant conditions has not been evaluated systematically \[[@CIT0005]\]. Here, we tested the virucidal activity of 8 commercially available oral rinses containing different active compounds against 3 different SARS-CoV-2 isolates under conditions mimicking nasopharyngeal secretions.

METHODS {#s1}
=======

Virus Strains and Propagation {#s2}
-----------------------------

To isolate SARS-CoV-2 at the University Ulm Medical Center (Ulm, Germany), 50 000 Vero E6 cells were seeded in 24-well plates in 500 µL medium incubated overnight at 37°C. The next day, medium was replaced by 400 µL of 2.5 µg/mL amphotericin B--containing medium. Then, 100 µL of throat swabs that tested positive for SARS-CoV-2 by reverse-transcription quantitative polymerase chain reaction was titrated 5-fold on the cells and incubated for 3--5 days. Upon visible cytopathic effect, supernatant was taken and virus expanded by inoculation of Vero E6 cells in 75 cm^2^ flasks and propagated as described above. Thereby, the viral isolates BetaCoV/Germany/Ulm/01/2020 (strain 2) and BetaCoV/Germany/Ulm/02/2020 (strain 3) were obtained. In Essen, Germany, SARS-CoV-2 was isolated from a nasopharyngeal swab of a patient suffering from coronavirus disease 2019 (COVID-19) and named UKEssen strain (strain 1). The swab was taken using a Virocult vial (Sigma, Germany). The Virocult medium was then incubated on Vero E6 cells cultured in Dulbecco's modified Eagle's medium containing 10% (v/v) fetal calf serum and supplemented with penicillin (100 IU/mL), streptomycin (100 µg/mL), ciprofloxacin (10 µg/mL), and amphotericin B (2.5 µg/mL). Five days after infection, the supernatant was harvested and cell debris was removed by centrifugation. Afterward, 100 µL of the clear supernatant was used for subsequent infection of fresh Vero E6 cells. After 5 days of incubation, the virus suspension was harvested and cleared from cellular debris by centrifugation and stored at --80°C. Viral titers of the 3 stocks were determined by endpoint dilution assay and the 50% tissue culture infective dose (TCID~50~/mL) was calculated.

Quantitative Suspension Test and Virus Titration {#s3}
------------------------------------------------

Virucidal activity was determined with a quantitative suspension test with 30-second exposure time. In brief, 1 part virus suspension was mixed with 1 part organic load mimicking respiratory secretions (100 μL mucin type I-S, 25 μL BSA Fraction V, and 35 μL yeast extract, all Sigma-Aldrich) and 8 parts of the oral rinse \[[@CIT0006]\]. Medium served as a control. Following 30 seconds of exposure time, activity was immediately stopped by serial dilution. TCID~50~/mL values were determined by crystal violet staining and subsequent scoring of the amounts of wells displaying cytopathic effects. TCID~50~ was calculated by the Spearman--Kärber algorithm. The titer reduction including its 95% confidence interval is calculated as the difference between the virus titer after contact with the oral rinse and the control virus titer with medium (reduction factor). Cytotoxic effects of oral rinses were monitored by crystal violet staining using noninfected cells and used to determine the lower limit of quantification (LLOQ). An optical analysis for altered density and morphology of the cellular monolayer in the absence of virus was performed and was quantified analogous to the TCID~50~/mL of the virus infectivity.

RESULTS {#s4}
=======

We examined the virucidal activity of 8 commercially available oral rinses based on different active compounds ([Table 1](#T1){ref-type="table"}) using a quantitative suspension test with 3 different SARS-CoV-2 isolates mixed with an interfering substance mimicking a respiratory secretion. A medium control after 30 seconds exposure time did not reduce viral infectivity, thus implying that the used interfering substance mimicking nasal secretions did not alter virus stability. In contrast, the different SARS-CoV-2 strains (strains 1--3) were highly susceptible to various oral rinses. Three of the 8 formulations, including product C, product E, and product F, significantly reduced viral infectivity to up to 3 orders of magnitude to background levels ([Figure 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). Also, for the other products containing different active compounds ([Table 1](#T1){ref-type="table"}), virucidal activities could be observed with log reduction factors ranging between 0.3 to 1.78 ([Figure 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). In the case of product H, which is based on polyhexamethylene biguanide, strain 1 was only moderately reduced, whereas the other 2 strains were inactivated to the LLOQ, which was determined by monitoring the cytotoxic effects of the products in noninfected cells ([Figure 1](#F1){ref-type="fig"}). In summary, we provide evidence that SARS-CoV-2 can be efficiently inactivated by commercially available oral rinses within short exposure times of 30 seconds.

###### 

Overview of Oral Rinses Used in the Study With Product Name, Active Compounds, and Calculated Reduction Factors

  ---------------------------------------------------------------------------------------------------------------------------
  Product   Trade Name                  Active Compound^a^                            Log Reduction Factor\           
                                                                                      (Mean of n = 3)                 
  --------- --------------------------- --------------------------------------------- ----------------------- ------- -------
  A         Cavex Oral Pre Rinse        Hydrogen peroxide                             0.78                    0.61    0.33

  B         Chlorhexamed Forte          Chlorhexidinebis (D-gluconate)                1.00                    0.78    1.17

  C         Dequonal                    Dequalinium chloride, benzalkonium chloride   ≥3.11                   ≥2.78   ≥2.61

  D         Dynexidine Forte 0.2%       Chlorhexidinebis (D-gluconate)                0.50                    0.56    0.50

  E         Iso-Betadine mouthwash 0%   Polyvidone-iodine                             ≥3.11                   ≥2.78   ≥2.61

  F         Listerine Cool Mint         Ethanol, essential oils                       ≥3.11                   ≥2.78   ≥2.61

  G         Octenident mouthwash        Octenidine dihydrochloride                    1.11                    0.78    0.61

  H         ProntOral mouthwash         Polyaminopropyl biguanide (polyhexanide)      0.61                    ≥1.78   ≥1.61
  ---------------------------------------------------------------------------------------------------------------------------

^a^The exact formulations for these oral rinses are not publicly available due to patent-related restrictions.

![Virucidal activity of oral rinses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 strains 1 (dot; UKEssen), 2 (square; BetaCoV/Germany/Ulm/01/2020), and 3 (triangle; BetaCoV/Germany/Ulm/02/2020) were incubated with medium (control) or various oral rinses for 30 seconds. Both conditions were supplemented with an interfering substance mimicking respiratory secretions. Viral titers were determined upon titration on Vero E6 cells. The cytotoxic effect was monitored using noninfected cells incubated with the different products, defined as the lower limit of quantification (LLOQ). The 50% tissue culture infectious dose (TCID~50~/mL) was calculated according to Spearman--Kärber. Data indicate averages and standard deviation of 3 independent experiments.](jiaa471f0001){#F1}

DISCUSSION {#s5}
==========

The main route of transmission of SARS-CoV-2 is suspected to involve direct contact with respiratory aerosols or droplets of infected individuals, produced during sneezing, coughing, or talking, and subsequent contact to nasal, oral, or ocular mucosal membranes \[[@CIT0001]\]. SARS-CoV-2 initially colonizes the upper respiratory tract of infected individuals \[[@CIT0002]\]. High viral loads in the oral cavity provide a rich source of potentially infectious virus as well as an entry route for new infections. Hence, if assuming that the throat functions as a major site of viral replication during early stages (even before symptom onset), oral antisepsis could lower the number of infectious aerosolized virus particles and consequently the risk of transmission or infection. Experimental and clinical research studies on SARS-CoV-2--related viruses (eg, severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses and influenza virus H5N1) showed that antiseptic solutions containing chlorhexidine gluconate, polyvinylpyrrolidone iodine, chlorine dioxide, cetylpyridinium chloride, and hydrogen peroxide can indeed reduce viral loads \[[@CIT0007]\]. We found that different SARS-CoV-2 strains can be efficiently inactivated with commercially available oral rinses under biologically relevant conditions mimicking respiratory secretions. In particular, we observed that 3 formulations (products C, E, and F) containing different active compounds significantly reduced viral infectivity to undetectable levels. In agreement with our observation, different studies using Listerine (product F) observed antiviral activities specifically against enveloped viruses, implying an impact on the viral lipid envelope \[[@CIT0008]\]. The in vivo effects of the oral solutions require further analysis during clinical studies. First trials with the aim to reduce the viral load in confirmed COVID-19 patients have been registered. One study aims to compare 3 antiseptic mouthwash/gargling solutions compared to a control (distilled water) to reduce SARS-CoV-2 load in 120 individuals with confirmed COVID-19 (<https://clinicaltrials.ucsf.edu/trial/NCT04409873>). Another blind, randomized controlled pilot trial plans to determine the potential of various gargling agents in reducing intraoral viral load among patients with laboratory-confirmed COVID-19 (<https://clinicaltrials.gov/ct2/show/NCT04341688>). Our findings clearly advocate the evaluation of selected formulations in clinical context to systematically evaluate the decontamination and tissue health of the oral cavity in patients and healthcare workers to potentially prevent virus transmission.
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